Loading Events

« All Events

  • This event has passed.

ABGH at AASLD 2021!

November 15, 2021

ABGH was well and fully represented at AASLD 2021!  Please take a moment to review the amazing scholarship from our members below!

Rotonya M. Carr, MD, FACP
University of Washington
Seattle, WA
 Obesogenic diet and alcohol induce metabolic dysfunction, steatosis, and glucose intolerance,
 Deletion of ceramide synthase 6 (CerS6) improves hepatic steatosis and glucose homeostasis in
ethanol-fed mice, POSTER
 Fecal metabolomic signatures of bile and amino acids distinguish patients with NASH in the
REGENERATE study compared to a healthy control population, POSTER OF DISTINCTION
 Long-term clinical outcomes of patients with COVID-19 and chronic liver disease, ORAL
 Diversity Committee Mentoring Session, MENTOR/SPEAKER

Jeremy Louissaint, MD
Columbia University Medical Center
 Patient portal use is associated with lower 90-day readmissions in decompensated cirrhosis,
 Clinical Practice SIG Poster Debrief, MODERATOR

Emmanuel McDonald DO, MBS
Larkin Community Hospital, South Miami
Miami, FL
 Autoimmune Hepatitis in a Patient with Sarcoidosis, POSTER

Lauren D. Nephew, MD, MAE, MSC
Indiana University School of Medicine
Indianapolis, IN
 Eliminating Health Disparities in Liver Disease, MEET THE EXPERT
 Increasing Rates or Non-Cirrhotic HCC in Black Patients A Multi-Center Cohort Study, ORAL
 Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment
Rates, But Disparities Persist, POSTER

Omar T. Sims, PhD
University of Alabama at Birmingham
Birmingham, AL
 Forecasting Future Hepatitis C Disease Burden Between Non-Hispanic Black, Non-Hispanic White,
and Hispanic Older Adults in the United States, POSTER

Ashley Spann, MD, MSACI
Vanderbilt University Medical Center
Nashville, TN
 Meet the Expert: Applying Machine Learning to Liver Disease
 The impact of rural residence, geoeconomics, and health literacy on liver transplant outcomes,
 Cirrhosis-related sarcopenia may never resolve after liver transplant, POSTER
 Septal ™ is the strongest echocardiographic predictor of the new diagnostic criteria for
cirrhotic cardiomyopathy for prediction of major adverse cardiovascular events after liver
transplantation, POSTER
 The utility of new versus old diagnostic criteria for cirrhotic cardiomyopathy in predicting major
adverse cardiovascular events after liver transplantation, POSTER
 Impact of Cirrhotic Cardiomyopathy on the Development of Acute Kidney Injury Among Patients
With Cirrhosis, POSTER
 The association of cirrhotic cardiomyopathy with liver disease severity, POSTER

Kidist K. Yimam, MD
California Pacific Medical Center
San Francisco, CA
 AASLD Global Outreach and Engagement Committee, COMMITTEE MEMBER
 Meeting the Challenges of Liver Health in Africa, SESSION SPEAKER


November 15, 2021


AASLD 2021